An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer.
Bottom Line: the decision whether to treat patients with non-metastatic colon cancer with adjuvant chemotherapy is determined by clinical staging, frequently resulting in over or undertreatment. gene expression data and clinical information from 232 stage 1-4 colon cancer patients were analysed to identify expression patterns predictive of recurrence.The signature was evaluated on an independent series of 60 stage 2 and 3 patients.Multivariate analysis showed the classifier to be associated with approximately three- to fourfold increased risk of recurrence. the prognostic gene expression signature is able to stratify stage 2 and 3 colon cancer patients into groups with significant differences in 5-year DFS, information that may ultimately reduce deaths from colon cancer.
Affiliation: ChipDX LLC, PO Box 286874, New York, NY 10128, USA. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: A modified version of the method described by Bair and Tibshirani (2004) was used to develop and train a predictive algorithm capable of stratifying patients into categories corresponding to low or high risk of disease recurrence (Figure 1). This approach uses CPH models to relate survival time to two ‘metagene' expression levels. These ‘metagenes' are the first two principle component linear combinations of the corresponding genes found to be significantly associated with recurrence, independent to clinical covariates. The prognostic significance of each gene was assessed using multivariate CPH regression models that included age at diagnosis, tumour grade and clinical staging. In this study, genes with patterns of expression that were significant at P<0.002 were used to compute the principle components and regression coefficients (weights).
Affiliation: ChipDX LLC, PO Box 286874, New York, NY 10128, USA. email@example.com